Source - SMW
Midatech Pharma has signed a global licensing agreement with Novartis for the oncology compound panobinostat. 

Panobinostat would be developed by Midatech for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG) as a continuation of its existing MTX110 program, and potentially for Glioblastoma (GBM).

In pre-clinical test models, panobinostat, which is a pan-HDAC inhibitor, demonstrated very high potency against DIPG tumour cell lines. 

In one such study panobinostat was the most effective of more than 80 anti-cancer agents tested.